Integrated approach reveals hypoallergenic peptides for safer immunotherapy in allergic conditions, implying new treatment possibilities.
This integrated approach identifies hypoallergenic peptides that selectively engage protective IgG responses and offers a framework for developing safer, next-generation immunotherapies for allergic disease.
No takes yet. Share an insight, caveat, or question.
Šošić et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: